Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2135632-29-8; 2135632-36-7; 2135632-30-1
Drug Levels and Effects
Summary of Use during Lactation
Inmazeb is a mixture of monoclonal antibodies, atoltivimab, maftivimab, and odesivimab that are directed against Zaire ebolavirus glycoprotein. No information is available on the use of Inmazeb during breastfeeding. Because Inmazeb is a mixture of large protein molecules with molecular weights of 144,000 to 146,000 Da, the amount in milk is likely to be very low and absorption is unlikely because the antibodies are probably destroyed in the infant's gastrointestinal tract. Until more data become available, Inmazeb should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The US Centers for Disease Control and Prevention recommend that patients with confirmed Zaire ebolavirus not breastfeed their infants to reduce the risk of postnatal transmission of Zaire ebolavirus infection.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Inmazeb
CAS Registry Number
2135632-29-8; 2135632-36-7; 2135632-30-1
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus.[Drugs Today (Barc). 2021]Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus.Saxena D, Kaul G, Dasgupta A, Chopra S. Drugs Today (Barc). 2021 Aug; 57(8):483-490.
- Review REGN-EB3: First Approval.[Drugs. 2021]Review REGN-EB3: First Approval.Markham A. Drugs. 2021 Jan; 81(1):175-178.
- Review Ansuvimab.[Drugs and Lactation Database (...]Review Ansuvimab.. Drugs and Lactation Database (LactMed®). 2006
- Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.[Front Immunol. 2021]Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.Gilchuk P, Guthals A, Bonissone SR, Shaw JB, Ilinykh PA, Huang K, Bombardi RG, Liang J, Grinyo A, Davidson E, et al. Front Immunol. 2021; 12:706757. Epub 2021 Jul 16.
- Review Caplacizumab.[Drugs and Lactation Database (...]Review Caplacizumab.. Drugs and Lactation Database (LactMed®). 2006
- Inmazeb - Drugs and Lactation Database (LactMed®)Inmazeb - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...